CNS Pharmaceuticals, Inc. Retained Earnings
CNS Pharmaceuticals, Inc. (CNSP) had Retained Earnings of -$107.80 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$107.80M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$105.21M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$100.28M; Retained Earnings (Accumulated Deficit) as first filed -$100.28M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$94.32M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$107.80M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$105.21M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$100.28M 10-Q · filed 2026-08-12 | -$100.28M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$94.32M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$91.10M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$88.73M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$84.42M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$81.25M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$75.64M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$73.11M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$69.57M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$64.19M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$59.67M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$55.65M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$50.72M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$44.75M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$41.33M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$37.77M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$35.44M 10-K · filed 2023-03-31 | -$34.98M 10-K · filed 2022-03-03 |
| 2021-09-30 | -$32.19M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$28.37M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | -$24.56M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$20.95M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$17.94M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | -$15.93M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$13.46M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$11.49M 10-K · filed 2021-02-12 | |
| 2019-09-30 | -$8.96M 10-Q · filed 2019-12-20 | |
| 2018-12-31 | -$7.61M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |